← Eichor
Study identifier: NCT06160323 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer

Condition: Pancreatic Cancer Non-resectable · Tumor Pancreas · Pain Cancer  ·  Sponsor: Chinese University of Hong Kong

PhaseNA
Planned participants94
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.

This description comes directly from the study's public registry record.

Talk to the study team

Shannon Melissa Chan  ·  852-35052627  ·  shannonchan@surgery.cuhk.edu.hk

Always discuss trial participation with your own doctor first.

Locations (1)

Prince of Wales HospitalHong Kong, Hong Kong, Hong KongRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06160323